Introduction
In advanced gastric cancer, the incidence of recurrence at a distant site is as high as 50%, despite prior extended lymph node dissection. The most common relapse site is the peritoneum. The detection of disseminated cancer cells in the peritoneal cavity is of great advantage when predicting peritoneal recurrence and patient prognosis [1] . We previously reported that the level of carcinoembryonic antigen (CEA) mRNA expression, adjusted against the GAPDH mRNA level in the peritoneal cavity, is a good predictor of peritoneal recurrence and is an independent prognostic factor in patients with gastric cancer [2] .
The second most frequent cause of treatment failure in gastric cancer is hematological recurrence, such as liver metastasis. To predict hematological recurrence, detection of disseminated cancer cells in bone marrow has been extensively investigated in breast [3] [4] [5] [6] , colorectal [7, 8] , and non-small-cell lung [9, 10] cancer. In breast cancer, the consensus is that the presence of disseminated cancer cells in the bone marrow is associated with a poor prognosis [6] . However, in gastric cancer, unlike breast cancer, the number of reports is limited, and no consensus has been reached regarding the correlation between the presence of disseminated tumor cells in bone marrow and patient survival. Significant correlation with disease-free or overall survival has been reported in studies using immunohistochemistry with anti-cytokeratin antibody [11] [12] [13] . However, Heiss et al. [14] reported that immunocytochemistry using cytokeratin (CK)-18 alone did not demonstrate a significant difference in survival, but that the addition of urokinase-type plasminogen activator receptor double staining did produce a significant difference in overall and disease-free survival. In addition, Schott et al. [15] reported that their peritoneal cavity results correlated with the 4-year survival rate, but positive results in the bone marrow showed little significance. Furthermore, no standardized procedure for detecting disseminated cancer cells in bone marrow has been established. Immunocytochemistry using monoclonal antibodies against CK is the most popular procedure; however, a recent molecular biological protocol using the realtime quantitative reverse transcription polymerase chain reaction (RQ-PCR) targeting CEA or CK appears to be an attractive method with high objectivity and quantifiability. Unlike immunocytochemistry, there had been few reports describing the usefulness of CK-18; on the contrary, CK-19 has been most extensively studied in breast cancer [5] , and promising results had been reported with CK-20 in gastric cancer [16, 17] as a marker for the PCR technique. Therefore, among the several kinds of CKs, CK-19 and CK-20 are thought to be good candidates for detecting disseminated cancer cells in bone marrow using RQ-PCR. Thus, to evaluate the clinical significance of detecting bone marrow-disseminated cancer cells in patients with gastric cancer, we investigated the CEA, CK-19, and CK-20 mRNA expression levels in bone marrow using RQ-PCR.
Materials and methods

Cell lines
The human gastric cancer cell line MKN-45, obtained from the Riken Cell Bank (Institute of Physical and Chemical Research, Saitama, Japan), and the human colon cancer cell line C-1, obtained from IBL Fujioka (Gunma, Japan) were incubated in RPMI-1640 medium containing 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO 2 .
Patients
A total of 65 patients (48 men, 17 women; age range 18-82 years, mean 64 years) who underwent gastrectomy and had histologically proven gastric carcinoma between November 2000 and April 2003 were enrolled in the study. Written informed consent was obtained from all patients. Tumor characteristics were determined according to the Japanese Classification of Gastric Carcinoma [18] and are listed in Table 1 . The depth of tumor invasion (T category) and extent of lymph node metastasis (N category) were determined by the histological diagnosis.
Macroscopic peritoneal metastasis was observed in three patients, and all of these patients were had positive cytology. Synchronous liver metastasis was confirmed in four patients. Of the 65 patients, 37 had a T1 tumor, 17 had a T2 tumor, 10 had a T3 tumor, and 1 had a T4 tumor. Lymph nodes were involved in 18 patients (N1 in 9 patients, N2 in 6 patients, N3 in 3 patients). Consequently, tumor stage was determined as IA in 33 patients, IB in 17 patients, II in 2 patients, IIIA in 2 patients, IIIB in 2 patients, and IV in 9 patients.
In one patient at stage IV, curative resection was enabled owing to extended peritoneal resection. Therefore, curative surgery involving gastrectomy and adequate lymphadenectomy (D0 in 4, D1 in 32, D2 in 23, and D3 in 6) was performed in 57 patients, and noncurative surgery involving simple gastrectomy without extended lymphadenectomy was performed in 8 patients. cells to one cell in the PBMCs, and the total number of cells then adjusted to 1 ¥ 10 7 cells. Total RNA was extracted from each cell fraction; and RQ-PCR for CEA, CK19, and CK20 mRNA was then performed as described below. The preliminary experiments indicated that the CK20 expression level was quite low in MKN-45 cells, and thus C-1 cells were used for the CK20 spiking analysis. In the present study, the threshold of detection of mRNA resulted in a detection rate of 1 cancer cell per 1 ¥ 10 7 PBMCs.
RNA extraction and cDNA synthesis
A 20-ml aliquot of bone marrow was aspirated from the sternum under general anesthesia at the time of surgery. Samples were centrifuged at 1500 g for 5 min before washing with cold phosphate-buffered saline (PBS). Cells were then suspended in Isogen reagent (NipponGene, Tokyo, Japan) and stored at -80°C.
Frozen cells in Isogene were thawed, and total RNA was extracted using the acid-guanidiniumisothiocyanate-phenol-chloroform method. Ethachinmate (Nippon Gene) was added to the samples as the RNA carrier. Before performing reverse transcription, total RNA was incubated with DNase I (Invitrogen) to remove contaminating genomic DNA. Total RNA (1 mg) was reverse-transcribed using a random hexamer (Applied Biosystems, Foster City, CA, USA) and SuperScript II reverse transcriptase (Invitrogen). The reaction mixture was incubated for 1 hat 37°C, then at 90°C for 10 min, and stored at -20°C. The integrity of the isolated RNA was established by RT-PCR analysis of the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as described elsewhere [1] .
Real-time quantitative polymerase chain reaction
CEA-, CK19-, and CK20-specific oligonucleotide primers and a fluorogenic probe were designed using Primer Express Software (Applied Biosystems). For CEA, the sense primer was 5¢-CAT GAT TGG AGT GCT GGT TG-3¢, and the anti-sense primer was 5¢-ACC AAG CCC AGC TCA TTT T-3¢. The fluorogenic probe was 5¢-(FAM) TTG CTC TGA TAT AGC AGC CCT GGT G (TAMRA)-3¢. For CK19, the sense primer was 5¢-ACC ATT GAG AAC TCC AGG ATT GTC-3¢, and the anti-sense primer was 5¢-CTC ATG CGC AGA GCC TGT T-3¢. The fluorogenic probe was 5¢-(FAM)CAG ATG ACT TCC GAA CCA AGT TTG AGA CG (TAMRA)-3¢. For CK20, the sense primer was 5¢-GAA CGC CCG AAC AAC GAA TA-3¢, and the anti-sense primer was 5¢-CAC GAC CTT GCC ATC CAC TA-3¢. The fluorogenic probe was 5¢-(FAM)TGA ACA GGA AAT TGC TAC TTA CCG CCG C (TAMRA)-3¢.
The RQ-PCR assay was performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The PCR reaction proceeded in a mixture (50 ml) containing 200 nM of each primer, 5 mM of probe, 25 ml of TaqMan Universal PCR Master Mix (Applied Biosystems), and 5 ml of cDNA template. Fifty cycles of amplification were performed at 95°C (15 s) and 60°C (1 min);and CEA, CK19, and CK20 mRNA expression levels were normalized against quantified GAPDH mRNA expression.
Statistical analysis
Statistical analysis was performed using a personal computer and StatView V.5.0 software (SAS Institute, Cary, NC, USA). The chi-squared test was used to evaluate the correlation between positive results and clinicopathological factors. Survival curves were calculated using the Kaplan-Meyer method and compared with the log-rank test. P < 0.05 was considered statistically significant. To evaluate the correlation between two variables, linear regression analysis using logarithmic data was performed, and Pearson's correlation coefficient was calculated (see Fig. 2, below) .
Results
Sensitivity of RQ-PCR and determination of threshold levels
Amplification plots for CEA and CK19 and CK20 in the cell spiking study using MKN45 and C-1 cells are shown in Fig. 1 . Specific amplification of each gene was observed at as low as one cancer cell in 1 ¥ 10 7 PBMCs. No amplification of CEA (Fig. 1A) or CK20 (Fig. 1C) was observed in the PBMCs alone; however, low-level amplification of CK19 was detected in PBMCs after 40 cycles, suggesting the presence of nonspecific amplification (Fig. 1B) .
The expressii Álevel of each gene normalized against GAPDH demonstrated linear correlation with the number of cells ranging from 1 ¥ 10 6 cells to one cell for each gene (Fig. 2) . We defined the mRNA expression level of 1 cell in 1 ¥ 10 7 PBMCs as the threshold for further analysis. 
Evaluation of expression of CEA, CK19, and CK20 mRNA in bone marrow
Samples from all 65 patients were evaluated for CEA, CK19, and CK20 mRNA using the RQ-PCR assay. Measurable amounts of CEA mRNA were detected in the samples from 4 of the 65 patients at the level ranging from 1.86 ¥ 10 -6 to 3.28 ¥ 10 -4 (mean 8.59 ¥ 10 -5 ). The CEA mRNA expression level in one patient was above the threshold and was judged positive. CEA mRNA expression was not detected in the remaining 61 samples. In these 61 samples, and in 3 samples with a CEA mRNA level below the threshold, CEA mRNA was defined as negative. Therefore, the positivity rate of CEA mRNA was 1 in 65 (1.5%) (Fig. 3A) .
CK19 mRNA was detected in samples from 59 of the 65 patients at levels ranging from 8.57 ¥ 10 -4 to 1.46 ¥ 10 -1 (mean 1.3 ¥ 10 -2
); none was detected in the remainder. In 1 of the 59 patients with detectable CK19 mRNA expression, the CK19 mRNA level was above the threshold and was judged positive. In 6 samples without positive amplification and in 58 with a CK19 mRNA level below the threshold, CK19 mRNA was classified as negative. The positive rate for CK19 was also 1 in 65 (1.5%) (Fig. 3B) . Measurable amounts of CK20 mRNA were detected from only one sample of the 65 patients, at the level of 7.15 ¥ 10 -4 . The CK20 mRNA expression level in this patient was above the threshold and was judged positive. Therefore, the positivity rate of CK20 mRNA was 1 in 65 (1.5%) (Fig. 3C) .
Using the CEA, CK19, and CK20 RQ-PCR assays, only 1 of the 65 patients (1.5%) was determined to be positive. The clinical features of this patient were T4, N3, and P1 (having peritoneal metastasis), and the tumor was classified as stage IV according to the Japanese Classification of Gastric Carcinoma with the histological type of poorly differentiated adenocarcinoma. He underwent palliative gastrectomy to relieve his symptoms and died of cancer 6 months after surgery. Of the 64 patients with negative mRNA expression in the bone marrow, 6 patients experienced recurrence (4 with hepatic metastasis, 2 with peritoneal metastasis) and died of cancer. No significant correlations were observed between CEA, CK19, or CK20 mRNA expression levels and clinicopathologic factors, including survival.
Discussion
In the present study, we quantitatively measured the expression levels of CEA, CK19, and CK20 using RQ-PCR to evaluate the clinical significance of bone marrow-disseminated cancer cells in patients with gastric cancer. The results were in stark contrast with previous findings of high bone marrow dissemination in patients with gastric cancer. We were able to detect bone marrow-disseminated cancer cells in only 1 of 65 patients with a variety of gastric cancer stages using a threshold level determined by cell spiking analysis.
The detection of disseminated cancer cells in bone marrow was first described in gastric cancer by Schlimok et al. [11] using immunocytochemistry with an anti-CK18 antibody. They reported that tumor cells in bone marrow were detected in 34 of 97 patients (35%). Thereafter, several investigators also demonstrated the presence of disseminated tumor cells in bone marrow using the same method and reported positivity rates of 33%-53% [12, 19, 20] . Soeth et al. [16] reported that CK20 mRNA-positive samples were detected in 11 of 49 (22%) gastric cancer patients using nested RT-PCR. Using RQ-PCR, Oki et al. [17] reported that CK20 mRNA was detected in 27 of 45 patients (60%). Compared with these results, the present data exhibit an extremely low positivity rate in bone marrowdisseminated cells.
One possible explanation may be the high incidence of early gastric cancer in our series, which included more than half of the early gastric cancer patients. The incidence of hematological recurrence is less than 10% in early gastric cancer, which might accordingly result in a low incidence of positive disseminated cells in bone marrow. However, this explanation is not entirely robust, as Maehara et al. [21] reported that cytokeratinpositive cells were detectable in 9 of 45 patients (20%), even with early gastric cancer.
The other possibility is the sensitivity of our assay method. With immunocytochemistry, one cancer cell per 1 ¥ 10 5 to 1 ¥ 10 6 bone marrow-derived cells is usually detectable [3, 22] . In contrast, one cancer cell per 1 ¥ 10 6 to 5 ¥ 10 7 bone marrow-derived cells or PBMCs is usually detectable by nested RT-PCR [23] or RQ-PCR [2, 17] using cell spiking analysis with positive expression cell lines as the target genes. In the present study, we were able to detect one cancer cell per 1 ¥ 10 7 PBMCs using the CEA, CK-19, and CK-20 genes. Therefore, the probability that the sensitivity of our system is lower than that of other studies using PCR technology or immunocytochemistry is slim.
The only probable explanation for our low positivity rate is the setting of the threshold level. For RQ-PCR, determining the threshold level is a problematic issue. In our previous study investigating CEA mRNA in peritoneal washings in patients with gastric cancer, we set the threshold at the mean plus two standard deviations of CEA mRNA levels in peritoneal washings from 20 patients with asymptomatic cholecystolithiasis (1.01 ¥ 10 -3
) [2] . In the present study, we used a threshold in which one cancer cell per 1 ¥ 10 7 PBMCs was detectable, which was much lower than that of our previous study. Yet, the positivity rate of CEA in the bone marrow samples was markedly lower than that in the peritoneal washings. CEA mRNA expression was detectable below the threshold level in three patients. However, even if treated as positive cases, there was still no correlation between CEA positivity and clinicopathological features or patient survival (data not shown).
In CK19, nonspecific amplification was observed after 40 cycles in the PBMCs-alone sample. Furthermore, the CK19 positivity rate changed according to the threshold level. For instance, when the threshold was set at 1 ¥ 10 -4 , the positivity rate was 35%. However, we were unable to find any threshold levels that showed clinical significance when the threshold was arbitrarily changed. One possible explanation may be found in the study by Ruud et al. [24] , in which they identified a novel pseudogene that shows a high degree of identity with the CK19 gene sequence. They also noted that the published primer sequences and reaction conditions used by several other groups to detect CK19 mRNA may have led to the amplification of this pseudogene. In line with this, previous work by others as well as the samples in the present study using CK19 as a marker need to be reassessed in the future.
The expression levels of CK20 were extremely low, except in one patient with very advanced disease. Oki et al. [17] investigated disseminated cancer cells in bone marrow using RQ-PCR in patients with gastric cancer and reported a CK20 positivity rate of 57%. This difference in positivity compared with the present results may be due to the different PCR conditions used, in particular the primer and probe sequences. However, the procedure by Oki et al. to determine the threshold level was not documented. Jung et al. [25] investigated the diagnostic specificity of CK20 mRNA detection and found that CK20-expressing cells were positively identified as belonging to the granulocyte fraction of leukocytes. They concluded that positive CK20 expression in normal granulocytes must be considered in tests designed to detect disseminated cancer cells.
Conclusion
Based on the present results, we conclude that the clinical significance of detecting disseminated cancer cells in bone marrow, in particular using RQ-PCR, is quite low in patients with gastric cancer. To utilize this technology in the clinical setting, optimal conditions, including target genes and a standardized detection method, must be established, and there should be a comparison with an immunocytochemical method.
